Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes

• DOI: 10.36469/jheor.2024.124111
• Publication Date: 2024-11-04T18:58:53Z
• Authors: Noelle Gronroos; Caroline Swift; Monica Frazer; Andrew Sargent; Michael Leszko; Erin Buysman; Sara Alvarez; Tyler Dunn; Josh No-one
• Keywords: Semaglutide

Background: Medical management of patients with type 2 diabetes mellitus (T2DM) is complex because the chronic nature disease and its associated comorbidities. Injectable once-weekly semaglutide for (OW sema T2D) a glucagon-like peptide–1 receptor agonist approved treatment T2DM. Objectives: To describe patient characteristics HbA1c changes prescribed 1.0 mg maintenance dose OW T2D. Methods: This retrospective study included adult T2DM pre-index glycated hemoglobin (HbA1c) at least 7%, initiating T2D between January 1, 2018, December 31, 2019, dose. Patients were identified in Optum Research Database if they had continuous health plan enrollment 12 months prior to (pre-index) following (post-index) date first claim (index). Dose initiation prescriber specialty captured. Change latest post-index measurement was calculated among all those 90 days (persistent patients). Results: A total 2168 this study. On average, taking 13.5 different classes medications. The majority lipid metabolism disorder (90.8%), hypertension (86.6%), complications (86.8%), or other nutritional/endocrine/metabolic disorders (72.5%). mean reduction 1.2% (P < .001). persistent (n =1280) 1.4% (SD) covered 236.1 (94.1) days. Discussion: Despite being medically complex, real-world experienced significant reductions Conclusions: an effective real world.